Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 650 of 866 entries
View as:

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05456685 Org: User:
Start: 09/28/22 End: 05/12/26 Due: 05/12/27

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03105102 Org: User:
Start: 04/09/18 End: 05/31/26 Due: 05/31/27

A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03360006 Org: User:
Start: 03/16/18 End: 12/19/20 Due: 12/19/21

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT03875482 Org: User:
Start: 05/13/19 End: 07/15/20 Due: 07/15/21

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

Phase: N/A Priority: Normal
NCT ID: NCT02691494 Org: User:
Start: 02/03/16 End: 01/23/19 Due: 01/23/20

BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT02684357 Org: User:
Start: 03/31/16 End: 09/30/17 Due: 09/30/18

UNITE Study: Understanding New Interventions With GBM ThErapy

Phase: N/A Priority: Normal
NCT ID: NCT03419403 Org: User:
Start: 07/30/18 End: 03/03/20 Due: 03/03/21

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03071757 Org: User:
Start: 03/21/17 End: 04/13/22 Due: 04/13/23

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT04480086 Org: User:
Start: 03/17/21 End: 07/28/23 Due: 07/28/24

A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia

Phase: N/A Priority: Normal
NCT ID: NCT05587049 Org: User:
Start: 11/30/23 End: 08/31/25 Due: 08/31/26

Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine

Phase: N/A Priority: Normal
NCT ID: NCT05861427 Org: User:
Start: 07/12/23 End: 03/01/25 Due: 03/01/26

Expanded Access to Rovalpituzumab Tesirine

Phase: N/A Priority: Normal
NCT ID: NCT03503890 Org: User:
Start: - End: - Due: -

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Phase: N/A Priority: Normal
NCT ID: NCT03086343 Org: User:
Start: 05/09/17 End: 06/06/23 Due: 06/06/24

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT04379050 Org: User:
Start: 06/08/20 End: 04/01/26 Due: 04/01/27

A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT01225302 Org: User:
Start: 09/30/10 End: 06/30/12 Due: 06/30/13

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection

Phase: N/A Priority: Normal
NCT ID: NCT02640482 Org: User:
Start: 11/30/15 End: 02/28/17 Due: 02/28/18

An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing Dupilumab

Phase: N/A Priority: Normal
NCT ID: NCT05394792 Org: User:
Start: 06/01/22 End: 08/15/24 Due: 08/15/25

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection

Phase: N/A Priority: Normal
NCT ID: NCT02604017 Org: User:
Start: 10/31/15 End: 01/31/17 Due: 01/31/18

A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)

Phase: N/A Priority: Normal
NCT ID: NCT04161898 Org: User:
Start: 02/04/20 End: 08/30/27 Due: 08/30/28

A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Phase: N/A Priority: Normal
NCT ID: NCT04994535 Org: User:
Start: 08/10/21 End: 06/14/23 Due: 06/14/24

A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting

Phase: N/A Priority: Normal
NCT ID: NCT05094128 Org: User:
Start: 11/22/21 End: 06/30/26 Due: 06/30/27

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03893955 Org: User:
Start: 05/21/19 End: 03/30/25 Due: 03/30/26

Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04655261 Org: User:
Start: 12/12/20 End: 11/09/21 Due: 11/09/22

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03406156 Org: User:
Start: 08/10/18 End: 07/12/23 Due: 07/12/24

A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT05507580 Org: User:
Start: 05/12/23 End: 08/15/24 Due: 08/15/25